IMCD, a global leader in the distribution and formulation of specialty chemicals and ingredients, has announced the acquisition of Daoqin Biological, a prominent distributor of food, nutraceutical, and functional nutrition ingredients in China. This acquisition strengthens IMCD’s foothold in the fast-growing food and life sciences sectors in China.

Along with Daoqin, IMCD has also acquired its affiliates Longyu International Trade (Shanghai), and Long’en Biotechnology (Guangzhou), in China.

Daoqin is recognized for its specialized distribution of innovative ingredients for the food, personal care, and pharmaceutical industries. The company is known for its deep technical expertise and customer-oriented solutions, supported by a dedicated technical team and a laboratory that focuses on providing cutting-edge, functional solutions. Based in Shanghai, Daoqin generated a revenue of approximately CNY 122 million (around EUR 16 million) in 2023 and employs 21 people.

The closing of the transaction is subject to customary closing conditions and is expected to be completed in the second quarter of 2025. Once finalized, the acquisition will allow IMCD to leverage Daoqin’s technical expertise and customer relationships to expand its offerings in the food and nutrition markets in China.

The acquisition aligns with IMCD’s strategic goal of expanding its business portfolio in the food and nutrition markets. Nicky Huang, Managing Director of IMCD China, expressed enthusiasm about the deal and said, "The addition of Daoqin marks another step in our journey to deepen our presence in the food and nutrition markets and broadens the scope of our life science business portfolio. We are excited to welcome Daoqin's talented team and leverage our complementary portfolios and technical expertise to enhance our offerings and capabilities in the local market."

Jack Ning, General Manager of Daoqin, shared his excitement about the merger, emphasizing the synergy between the two companies. "The Daoqin team is excited to join IMCD, as we believe there are strong synergies between our businesses and capabilities. By leveraging IMCD’s exceptional global network and resources, we look forward to bringing greater innovation and value to customers in the life sciences markets in China," Ning said.

The transaction will bolster IMCD’s ability to offer innovative solutions to customers in China’s fast-evolving food, nutraceutical, and life science sectors. Daoqin’s strong relationships with leading suppliers and its established market presence in China will complement IMCD’s global network and strengthen its position in the Chinese market.

This acquisition will also enable Daoqin to tap into IMCD's expansive global network and enhanced resources, helping to drive further innovation and growth in the Chinese market. Daoqin’s expertise in food and nutraceutical ingredients is expected to further strengthen IMCD’s presence in these high-demand sectors.